Janux Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Alan Campbell
- Full Time Employees
- 91
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11099 North Torrey Pines Road San Diego CA United States of America 92037
- IPO Date
- Jun 11, 2021
- CIK
- 0001817713
- Website
- januxrx.com
- Similar Companies
- Business
- Janux Therapeutics, Inc. Janux Therapeutics, Inc. (JANX) is a clinical-stage biopharmaceutical company that develops precision-engineered tumor-activated T cell engagers (TRACTr), T cell co-stimulatory inhibitors (TRACIr) and agonist receptor modulators (ARM) to treat cancer and autoimmune diseases by selectively modulating T cells while minimizing systemic toxicity. The company offers a broad pipeline of wholly owned and partnered product candidates, including JANX007, a PSMA-targeted TRACTr in Phase 1b expansion for metastatic castration-resistant prostate cancer (mCRPC) in taxane-naïve, taxane-experienced, PARP inhibitor-resistant and novel hormonal therapy-experienced patients; JANX008, an EGFR-targeted TRACTr in Phase 1 for solid tumors such as colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer; preclinical PSMAxCD28 TRACIr to enhance T cell survival with JANX007; TROP2-targeted TRACTr for TROP2-positive tumors; and CD19-ARM for autoimmune diseases with an investigational new drug application planned for late 2025; alongside partnered TRACTr programs with Merck & Co., Inc. Merck & Co., Inc. targeting epidermal growth factor receptor, prostate specific membrane antigen and trophoblast antigen 2. Janux Therapeutics, Inc. operates primarily in the United States with global development potential through collaborations, targets oncology and immunology patient populations with high unmet needs, and maintains headquarters in San Diego, California, where it was founded in 2017. Recent developments include the achievement of a clinical milestone in the TRACTr collaboration with Merck & Co., Inc. in August 2025, triggering milestone payments and advancing the first partnered program into Phase 1; initiation of Phase 1b expansion studies for JANX007 in May 2025 supported by Phase 1a data showing 100% PSA50 declines, 63% PSA90 declines and median radiographic progression-free survival of 7.5 months in 16 mCRPC patients; plans for additional Phase 1b studies combining JANX007 with androgen receptor inhibitors and updates on JANX007 and JANX008 in the second half of 2025; and progression of three preclinical programs toward the clinic in 2026.
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
Here's Why You Should Add JANX Stock to Your Portfolio Now
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors